source
- Mineralys makes money moves before looming hypertension approvalMineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug called lorundrostat. It came with a tiny $1 million upfront fee to the medicine's originator,…Endpoints · 1mo ago↗ source
- Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseasesLast month, Ascidian Therapeutics presented the first data suggesting a new way to fix broken genes may be safe in people. Now Eli Lilly has struck a deal with the startup. Ascidian’s ...Endpoints · 1mo ago↗ source
- Lilly, Ascidian link up in RNA exon editing pactWorth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.